Investigation by the EU Reveals No Association Between Weight Loss and Diabetes Medications such as Wegovy and Ozempic and Suicidal Thoughts
A recent investigation conducted by the European Medicines Agency (EMA) has found no evidence linking popular weight loss and diabetes medications, such as Wegovy and Ozempic, to an increased risk of suicidal thoughts and self-injury. The nine-month review focused on GLP-1s, a class of drugs that mimic a hormone produced in the gut to suppress appetite. Despite their high demand and cost, these medications have faced concerns over potential side effects and risks.
The EMA’s investigation included drugs from Novo Nordisk, such as Wegovy and Ozempic, but did not cover Eli Lilly’s Zepbound and Mounjaro, two versions of the same drug. However, the active ingredient in Eli Lilly’s older diabetes treatment called Trulicity was part of the probe. Novo Nordisk has yet to provide a comment on the EMA’s findings.
This verdict from the European agency adds to a series of reassuring reports regarding the suicide risk associated with GLP-1s. The U.S. Food and Drug Administration (FDA) reached a similar conclusion in January, stating that while they couldn’t definitively rule out a small risk, there was no conclusive evidence linking these drugs to suicidal thoughts.
Clinical trials conducted by both Novo Nordisk and Eli Lilly have not demonstrated a connection between GLP-1s and suicidal thoughts. Nevertheless, researchers and doctors have remained vigilant in monitoring for any new side effects or risks as more patients begin taking these medications.
The EMA initiated the investigation after the Icelandic Medicines Agency flagged three cases of suicidal thoughts and self-injury in patients using drugs containing liraglutide and semaglutide, which are active ingredients in popular treatments. Semaglutide is used in Wegovy, Ozempic, and Novo Nordisk’s diabetes pill Rybelsus, while liraglutide is found in Novo Nordisk’s older weight loss drug Saxenda. The probe also included other active ingredients in older weight loss and diabetes drugs.
According to the EMA, the results of a large U.S. study and another study conducted by the agency itself did not find a direct association between the use of semaglutide and suicidal thoughts. Both studies were based on electronic health records, providing valuable insights into the safety profile of these medications.
It is important to note that if you or someone you know is experiencing suicidal thoughts or distress, it is crucial to seek support and assistance from trained professionals. In the U.S., the Suicide & Crisis Lifeline can be reached at 988, while the Samaritans in the U.K. can be contacted at 116 123.
Overall, the investigation by the EU has provided reassurance regarding the safety of weight loss and diabetes medications like Wegovy and Ozempic. With no evidence of an association between these drugs and suicidal thoughts, patients can feel confident in their treatment choices. As further research continues, it is essential for healthcare providers to remain vigilant in monitoring any potential side effects or risks associated with these medications.
